Actively Recruiting

All Genders
Healthy Volunteers
NCT03872102

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

Led by University of Texas Southwestern Medical Center · Updated on 2026-01-27

90

Participants Needed

1

Research Sites

405 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.

CONDITIONS

Official Title

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Parkinson disease with sufficient clinical data to determine progression rate (fast or slow) and availability of a matched participant in the alternate progression group
  • Willingness to participate in required imaging studies and provide written informed consent
  • Parkinson disease duration less than 5 years for newly recruited PD subjects
  • Multiple system atrophy diagnosis less than 5 years for newly recruited MSA subjects
  • Probable progressive supranuclear palsy diagnosis for PSP subjects, willing to participate in imaging and clinical visits
  • Control subjects roughly age and sex matched with PD cohort, with no history or signs of neurodegenerative disease and normal gait, balance, and eye movements for age
  • Subjects and investigators agree participant is likely able to complete the 2-year study without plans to move
Not Eligible

You will not qualify if you...

  • Contraindications to multimodal imaging
  • Females of child-bearing potential aged 18-55 unless pregnancy test confirms not pregnant prior to scanning
  • Non-English speakers
  • Right-handed finger amputees or with cast on right hand/fingers at enrollment
  • Clinically significant liver, kidney, lung, metabolic, hormone, heart, infectious disease, or medical comorbidity posing safety risk
  • History of severe drug allergy or hypersensitivity
  • History of drug, alcohol, or substance dependence or abuse within last year or prolonged prior history
  • Currently undergoing chemotherapy or radiation for cancer
  • Recreational drug use in past six months
  • Central nervous system disease or brain injury precluding participation
  • Psychiatric or neurological disorder precluding participation
  • Inability to keep or maintain research appointments
  • Severe disease progression making imaging participation impossible or difficult (Aim 1)
  • Absence of suitable matched participant in alternate progression group (Aim 1)
  • For PD subjects: presence of cerebellar abnormalities, downward vertical gaze limitation, diagnosis of frontotemporal dementia or primary progressive aphasia, parkinsonian features limited to lower limbs over 3 years, dopamine blocker treatment, no levodopa response, alternative diagnosis more likely, rapid gait impairment progression, no motor symptom progression, early bulbar dysfunction, respiratory dysfunction, severe early autonomic failure, recurrent falls, dystonic contractures, absence of common non-motor PD features, unexplained pyramidal signs, or bilateral symmetric parkinsonism (Aim 2)
  • For MSA subjects: significant neuropathy, non-drug-induced hallucinations, onset after age 75, family history of ataxia or parkinsonism, white matter lesions suggesting multiple sclerosis (Aim 2)
  • For PSP subjects: unexplained episodic memory impairment, autonomic failure, visual hallucinations, upper and lower motor neuron signs, sudden or rapid symptom progression suggestive of other diseases, history of encephalitis, prominent appendicular ataxia, identifiable cause of postural instability (Aim 2)
  • Control subjects deemed unsuitable by investigator (Aim 2)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

Loading map...

Research Team

P

Padraig E O'Suilleabhain, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here